乐卫玛

Linifanib.

出版信息

Drugs R D. 2010;10(2):111-22. doi: 10.2165/11584520-000000000-00000.

PMID:20698720

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3586091/

Abstract

Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. It was being developed by Roche but development has now reverted to Abbott. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. This review discusses the key development milestones and therapeutic trials of this drug.

摘要

利尼伐尼（A 741439；A-741439；A741439；ABT-869；ABT869；RG3635）是一种口服活性的多靶点受体酪氨酸激酶抑制剂，用于治疗各种癌症。它由罗氏开发，但现在已归雅培所有。该化合物旨在抑制血管内皮生长因子和血小板衍生生长因子受体。它目前正处于肝癌的 III 期开发阶段，在美国、欧盟和世界其他地区处于非小细胞肺癌、乳腺癌和结直肠癌的 II 期开发阶段。这篇综述讨论了该药的关键开发里程碑和治疗试验。